PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|September 2, 2013
- Pharmaceutical Technology-09-02-2013
- Volume 37
- Issue 9
MF40 Automated Punch and Die Polishing Machine
I Holland has introduced the next generation to its range of MF polishers, the MF40 automated punch, and die polishing machine.
I Holland has introduced the next generation to its range of MF polishers, the MF40 automated punch, and die polishing machine. The stainless-steel construction is highly durable and easy to clean, according to the company. A 40 L media drum and increased capacity holders allow for up to17 B or 12 D punches per holder giving a maximum of 51 B or 36 D punches per polishing cycle. The MF40 uses single-phase power and fits in the same compact 940 x 750 mm footprint as the MF35. The MF40 polishing machine was developed to be used as part of I Holland’s PharmaCare 7-Step Process, a professional maintenance and storage program.
Articles in this issue
about 13 years ago
The Importance of Continued Investment in R&Dabout 13 years ago
FDA Works to Secure Drug Supply Chainabout 13 years ago
Outsourcing Partnerships for CMC Developmentabout 13 years ago
Quality by Design in APIsabout 13 years ago
Connecting People, Science, and Regulationabout 13 years ago
Effective and Efficient Weighing of Potent Compoundsabout 13 years ago
EU Raises API Standards: A Curse in Disguise?about 13 years ago
The Importance of Characterization in Biosimilars Developmentabout 13 years ago
Omega Design Corporation Introduces LabelSync 450about 13 years ago
Bosspak VTC 100 Tablet and Capsule CounterRelated to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
4
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
5